hVIVO (LON:HVO) Earns Add Rating from Peel Hunt

Key Points

• Peel Hunt has reissued an "add" rating for hVIVO (LON:HVO) with a target price of GBX 21 ($0.28), indicating a potential upside of 120.80% from its previous close.
• Shore Capital has also given hVIVO a "buy" rating, setting a higher target price of GBX 35 ($0.47) in a separate research note.
• As of Tuesday, hVIVO stock was trading down 4.9% at GBX 9.51 ($0.13), with a market capitalization of £67.30 million.

Peel Hunt reiterated their add rating on shares of hVIVO (LON:HVO - Free Report) in a research note issued to investors on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has a GBX 21 ($0.28) price objective on the stock.

Separately, Shore Capital reissued a "buy" rating and issued a GBX 35 ($0.46) target price on shares of hVIVO in a research report on Tuesday, July 22nd.

hVIVO Price Performance

HVO stock traded up GBX 0.25 ($0.00) on Tuesday, hitting GBX 10.50 ($0.14). 3,685,997 shares of the company's stock traded hands, compared to its average volume of 3,213,829. hVIVO has a 1-year low of GBX 6.50 ($0.09) and a 1-year high of GBX 30.45 ($0.40). The stock has a market cap of £74.30 million, a price-to-earnings ratio of 4.33 and a beta of 0.97. The stock has a fifty day moving average of GBX 11.24 and a 200-day moving average of GBX 14.98. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.